2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-131089
    MC-VC-PABC-C6-α-Amanitin
    		98.88%
    MC-VC-PABC-C6-α-Amanitin is a Drug-Linker Conjugates for ADC, consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a MC-VC-PABC-C6 linker. Among them, alpha-Amanitin is a potent inhibitor of RNA polymerase IIα.
    MC-VC-PABC-C6-α-Amanitin
  • HY-164835
    VcMMAE-Deruxtecan
    		98.10%
    VcMMAE-Deruxtecan (SMP-54418) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Exatecan (HY-13631) (DNA topoisomerase I inhibitor). VcMMAE-Deruxtecan can be used for ADC synthesis.
    VcMMAE-Deruxtecan
  • HY-148245
    OH-Glu-Val-Cit-PAB-MMAE
    		99.03%
    OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    OH-Glu-Val-Cit-PAB-MMAE
  • HY-141147
    7-O-(Amino-PEG4)-paclitaxel
    		99.8%
    7-O-(Amino-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Amino-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs).
    7-O-(Amino-PEG4)-paclitaxel
  • HY-164995
    L1BC8
    		99.20%
    L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)).
    L1BC8
  • HY-W190943
    Azido-PEG4-Val-Cit-PAB-MMAE
    		99.43%
    Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH. Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azido-PEG4-Val-Cit-PAB-MMAE
  • HY-153947
    PB089
    		99.98%
    PB089 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.
    PB089
  • HY-171176
    2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan
    2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a drug-linker conjugate for ADC. 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is composed of linker and Exatecan (HY-13631).
    2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan
  • HY-19811
    Fmoc-Val-Cit-PAB-MMAE
    		98.85%
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC.
    Fmoc-Val-Cit-PAB-MMAE
  • HY-15742
    Vc-MMAD
    		99.96%
    Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a agent-linker conjugate for ADC.
    Vc-MMAD
  • HY-126683
    Mal-C6-α-Amanitin
    		98.48%
    Mal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.
    Mal-C6-α-Amanitin
  • HY-147281
    BAY 1135626
    		99.19%
    BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research.
    BAY 1135626
  • HY-131451
    Mc-Phe-Lys-PAB-MMAE
    Mc-Phe-Lys-PAB-MMAE (Compound 2) is a drug-linker conjugate for ADC, and can be used for synthesis of ADCs.
    Mc-Phe-Lys-PAB-MMAE
  • HY-160807
    DBM-GGFG-NH-O-CO-Exatecan
    DBM-GGFG-NH-O-CO-Exatecan is an inhibitor for topoisomerase I. DBM-GGFG-NH-O-CO-Exatecan can be used as a drug-linker conjugate for synthesis of ADC molecule.
    DBM-GGFG-NH-O-CO-Exatecan
  • HY-164788
    GGFG-PAB-MMAE
    		99.27%
    GGFG-PAB-MMAE (Comp 58054-1) is a drug-linker conjugate for ADC. GGFG-PAB-MMAE contains the ADC linker (GGFG-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
    GGFG-PAB-MMAE
  • HY-170400
    LNK4-S
    LNK4-S is a drug-linker conjugate, that can be used for synthesis of ADC molecule M-VA-EXA and F-VA-EXA.
    LNK4-S
  • HY-15740
    Mc-MMAD
    		98.39%
    Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a agent-linker conjugate for ADC.
    Mc-MMAD
  • HY-136261
    DM1-PEG4-DBCO
    		98.04%
    DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DM1-PEG4-DBCO
  • HY-147307
    MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan
    		99.55%
    MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a agent-linker conjugate for ADC, contains the ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan synthesized ADC can be used in study of cancer.
    MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan
  • HY-112615
    NAMPT inhibitor-linker 1
    		99.27%
    NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC50s of <3 pM and 9 pM, respectively.
    NAMPT inhibitor-linker 1
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.